Evidence map›Paper›PMID 31990315›Full record

ArticleJAMA2020

Yield of a Public Health Screening of Children for Islet Autoantibodies in Bavaria, Germany.

Anette-Gabriele Ziegler, Kerstin Kick, Ezio Bonifacio, Florian Haupt, Markus Hippich, Desiree Dunstheimer, Martin Lang, Otto Laub, Katharina Warncke, Karin Lange and 5 more

2 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in JAMA, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 167 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
167citing papers in PubMed, 9 pooled it
26.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05841719 nacompletednot on this mapstarted 2023, after this paper: background citation

General Population Universal Capillary Screening for Chronic Autoimmune, Metabolic and Cardiovascular Diseases (UNISCREEN): Feasibility and Acceptability Pilot Study.

TypeinterventionalSponsorEmanuele BosiRan2023 to 2024Enrolled1,535ConditionsCardiovascular Risk Factors, Autoimmune DiseasesArmsScreening test
NCT06006468 completednot on this mapstarted 2023, after this paper: background citation

Evaluating ImmuNe Changes in the Evolution of Pre Type 1 Diabetes With Adult Onset

TypeobservationalSponsorRoyal Devon and Exeter NHS Foundation TrustRan2023 to 2023Enrolled2,250ConditionsType 1 Diabetes, Type 1 Diabetes Mellitus Maturity OnsetArmsHigh genetic risk for type 1 diabetes, High gentic risk for Coeliac disease
3 · Its place in the literature

Who cites it

167 citing papers in PubMed, 9 syntheses or guidelines pooled it, 268 citations in OpenAlex.

  1. Pooled it
  2. Impact of screening programmes for type 1 diabetes in youth: A systematic review and meta-analysis.Diabetic medicine : a journal of the British Diabetic Association · 2026
    Pooled it
  3. Guideline
  4. Guideline
  5. Pooled it
  6. Guideline
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Well, How Did We Get Here? The Current State of Pediatric Endocrinology.Journal of pediatrics. Clinical practice · 2026
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

107 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 1 country.

Anette-Gabriele ZieglerInstitute of Diabetes Research, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany.
Kerstin KickInstitute of Diabetes Research, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany.
Ezio BonifacioDFG Center for Regenerative Therapies Dresden, Technische Universität Dresden, Dresden, Germany.
Florian HauptInstitute of Diabetes Research, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany.
Markus HippichInstitute of Diabetes Research, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany.
Desiree DunstheimerKlinikum Augsburg, Klinik für Kinder und Jugendliche, Augsburg, Germany.
Martin LangBerufsverband der Kinder- und Jugendärzte e.V., Landesverband Bayern, Augsburg, Germany.
Otto LaubPaedNetz Bayern e.V., Rosenheim, Germany.
Katharina WarnckeDepartment of Pediatrics, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.
Karin LangeDepartment of Medical Psychology, Hannover Medical School, Hannover, Germany.
Robin AssfalgInstitute of Diabetes Research, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany.
Manja JolinkInstitute of Diabetes Research, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany.
Christiane WinklerInstitute of Diabetes Research, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany.
Peter AchenbachInstitute of Diabetes Research, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany.
Fr1da Study Group
German Center for Diabetes Research · DEBayer (Germany) · DEBerufsverband der Frauenärzte · DEHeinrich Heine University Düsseldorf · DEMedizinische Hochschule Hannover · DETechnical University of Munich · DETechnische Universität Dresden · DEUniversity Hospital Augsburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

importancePublic health screening for type 1 diabetes in its presymptomatic stages may reduce disease severity and burden on a population level.

objectiveTo determine the prevalence of presymptomatic type 1 diabetes in children participating in a public health screening program for islet autoantibodies and the risk for progression to clinical diabetes. DESIGN, SETTING, AND

participantsScreening for islet autoantibodies was offered to children aged 1.75 to 5.99 years in Bavaria, Germany, between 2015 and 2019 by primary care pediatricians during well-baby visits. Families of children with multiple islet autoantibodies (presymptomatic type 1 diabetes) were invited to participate in a program of diabetes education, metabolic staging, assessment of psychological stress associated with diagnosis, and prospective follow-up for progression to clinical diabetes until July 31, 2019. EXPOSURES: Measurement of islet autoantibodies. MAIN OUTCOMES AND MEASURES: The primary outcome was presymptomatic type 1 diabetes, defined by 2 or more islet autoantibodies, with categorization into stages 1 (normoglycemia), 2 (dysglycemia), or 3 (clinical) type 1 diabetes. Secondary outcomes were the frequency of diabetic ketoacidosis and parental psychological stress, assessed by the Patient Health Questionnaire-9 (range, 0-27; higher scores indicate worse depression; ≤4 indicates no to minimal depression; >20 indicates severe depression).

resultsOf 90 632 children screened (median [interquartile range {IQR}] age, 3.1 [2.1-4.2] years; 48.5% girls), 280 (0.31%; 95% CI, 0.27-0.35) had presymptomatic type 1 diabetes, including 196 (0.22%) with stage 1, 17 (0.02%) with stage 2, 26 (0.03%) with stage 3, and 41 who were not staged. After a median (IQR) follow-up of 2.4 (1.0-3.2) years, another 36 children developed stage 3 type 1 diabetes. The 3-year cumulative risk for stage 3 type 1 diabetes in the 280 children with presymptomatic type 1 diabetes was 24.9% ([95% CI, 18.5%-30.7%]; 54 cases; annualized rate, 9.0%). Two children had diabetic ketoacidosis. Median (IQR) psychological stress scores were significantly increased at the time of metabolic staging in mothers of children with presymptomatic type 1 diabetes (3 [1-7]) compared with mothers of children without islet autoantibodies (2 [1-4]) (P = .002), but declined after 12 months of follow-up (2 [0-4]) (P < .001). CONCLUSIONS AND RELEVANCE: Among children aged 2 to 5 years in Bavaria, Germany, a program of primary care-based screening showed an islet autoantibody prevalence of 0.31%. These findings may inform considerations of population-based screening of children for islet autoantibodies.

Indexed as

Mass ScreeningAsymptomatic DiseasesAutoantibodiesChild, PreschoolDiabetes Mellitus, Type 1FemaleFollow-Up StudiesGermanyHumansIslets of LangerhansMaleParentsSurveys and QuestionnairesAutoantibodies

Identifiers

PMID31990315
PMCPMC6990943
OpenAlexW3003622489

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.